After looking at the data I'm going with sof/dac. And not really for financial reasons, I had thought of hitting it hard with sof/dac/led/rib.
I'll know in another week or so what my liver looks like and I'll skip the rib if it looks like I don't really need it. And I've got a bit of an agenda now.
So Mr. Time, here's what you can do to help humanity .... and I'm serious.
In the US dac is only approved for type 3. Gilead has been unwilling to participate in trials with BMS ... not in their financial interest.
Essentially BMS is limited here to a small subset of HCV patients. As I understand, in Europe sof/dac is approved across all types, but just how many countries are following the US lead on this? I don't know, but my understanding is that most of Gileads income so far has been in the US anyway. BMS seems content to not price compete and take their type 3 profits.
Let's push them.
If the results are as good as anticipated, and if enough of us are tracked by our good doctor here, and if he publishes his results, that uncertainty statistic drops ...... BMS just might decide to price compete. The Indian generic makers might decide to make sof/dac tabs hitting Gileads royalties. AbbVie might decide they have to price compete or miss out entirely.
What do you say?